Edesa develops treatments for dermatological and anorectal diseases. Edesa merged with Stellar Biotechnologies in 2019.
Edesa Biotech has raised $2.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
Edesa Biotech's investors include Government of Canada, Inveready, Lumira Ventures, Pharmascience, Nantahala Capital Management.
Edesa Biotech is headquartered in Markham, Canada.
Edesa develops treatments for dermatological and anorectal diseases. Edesa merged with Stellar Biotechnologies in 2019.
Edesa Biotech is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Edesa Biotech — Funding & Investors." VCBacked, June 11, 2026, https://www.vcbacked.co/company/edesa-biotech. Accessed August 5, 2026.
VCBacked. (2026). Edesa Biotech — Funding & Investors. Retrieved August 5, 2026, from https://www.vcbacked.co/company/edesa-biotech
{{cite web |title=Edesa Biotech — Funding & Investors |url=https://www.vcbacked.co/company/edesa-biotech |website=VCBacked |access-date=August 5, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated